Company Announcement no. 33/2007
To: OMX Nordic Exchange Hørsholm, Denmark, December 20, 2007
LifeCycle Pharma Announces Agreement with Top 10 Pharmaceutical Company for the
use of MeltDose® Technology
Hørsholm, Denmark, December 20, 2007; LifeCycle Pharma A/S (OMX: LCP) (the
“Company” or “LCP”), an emerging specialty pharmaceutical company, today
announced that it has signed a collaboration Agreement with a Top 10
pharmaceutical company (“pharma company”). Per the terms of the agreement, the
pharma company will use LCP's MeltDose® technology to conduct a preclinical
feasibility study in order to investigate a new formulation of one of its
product candidates. No financial terms were disclosed.
“We are very pleased that a one of the largest and most well known
pharmaceutical companies has decided to use our MeltDose® technology to
investigate its applicability to one of its product candidates, “stated
Flemming Ornskov, President and Chief Executive Officer. “We believe it is a
testament to the validity and broad application of our MeltDose® technology
platform.”
About LCP's MeltDose® Technology Platform
MeltDose® is LCP's proprietary drug delivery platform developed for the
improvement of absorption and bioavailability in oral therapeutics. The benefits
of MeltDose® over other drug delivery alternatives such as conventional and
nanocrystal technology include: decreased inter- and intra-individual
variability; reduction of food-effect; reduction in peak to trough ratio; and
reduction of administration frequency. For further information or to view the
MeltDose® animation, please visit:
http://lcpharma.com/technology0/meltdosetechnologyplatform
About LifeCycle Pharma A/S (“LCP”)
LCP is an emerging specialty pharmaceuticals company that, through innovative
technologies, is able to rapidly develop a portfolio of differentiated products
to meet the unique needs of key therapeutic markets and patient populations.
This includes products for immunosuppression, specifically organ
transplantation, and to combat certain cardiovascular diseases. By using its
unique and patented delivery technology, MeltDose®, LCP is able to develop drugs
with enhanced absorption and thereby increased bioavailability. Currently, the
Company has a diversified near- and medium-term pipeline, including a product
ready for US commercialization, five product candidates in clinical trials and
three in preclinical stages of development. LCP is listed on the OMX Nordic
Exchange under the trading symbol (OMX: LCP). For further information, please
visit www.lcpharma.com.
Contact:
LifeCycle Pharma A/S
Michael Wolff Jensen, +45 4074-6244
EVP and
CFO
MWJ@lcpharma.com
or
Francesca M. DeMartino
Director, Investor Relations & Corporate Communications
(917) 747-4938; FDM@lcpharma.com
LifeCycle Pharma Announces Agreement with Top 10 Pharmaceutical Company for the use of MeltDose® Technology
| Source: Veloxis Pharmaceuticals A/S
Attachments
